Latest Multi-drug-resistant tuberculosis Stories
Research led by St.
Immunitor, Inc., a commercial stage company committed to developing oral therapeutic vaccines, today announced that its second Phase II trial of oral TB vaccine with heat-killed Mycobacterium
Lauds Reduction in New Infections and Lowered Mortality Rate of TB; Urges More Aggressive Identification of Nearly 3 Million “Missed” New Cases of TB Annually and Greater Focus on More Virulent
Immunitor company announces publication of a successful clinical trial in 43 patients with tuberculosis who were given daily pill of therapeutic vaccine containing heat-killed Mycobacterium vaccae.
Virtual observation of patients taking their prescribed TB medication, could prove an effective technique for ensuring patients effectively complete their course of treatment.
Results of a new study suggest that three new diagnostic tests could each be used to successfully diagnose drug resistance in tuberculosis (TB) patients in a quarter of the time taken by the current method.
A new study has calculated the average cost per case of TB in the EU.
The immune response to the bacterium that causes tuberculosis (TB) varies between patients of different ethnic origin, raising important implications for the development of tests to diagnose and monitor treatment for the disease.
- The relation of a son or daughter to a parent: the correlative of paternity.
- The establishment of a filial relation, specifically by adoption.